Immunogenic Cell Death Markers in Liver Cancer

Living reference work entry
First Online:
Received:
Accepted:

Abstract

Primary and secondary liver cancers are still a major medical and social problem due to the often late diagnosis and poor prognosis. Therefore meaningful biomarkers for better diagnosis, therapy stratification, and monitoring are highly needed. Beyond conventional clinical and tumor markers, immunogenic cell death (ICD) markers are promising new candidates. They comprise an inhomogeneous group of molecules that are released from apoptotic or necrotic cells. In blood, these danger-associated molecular patterns (DAMPs) such as the high-mobility group box 1 protein (HMGB1) are able to exert activating and suppressive effects on the immunity system and promote tumor growth and invasiveness.

Here, we review the pathophysiology of primary and secondary liver cancer, the current therapeutic approaches, and the role of immunogenic cell death markers for the development and progression of cancer disease. Further, we report on their relevance as serum biomarkers for the diagnosis, estimation of prognosis, as well as the prediction and monitoring of response to cytotoxic therapy in cancer patients.

Keywords

Liver cancer metastasis immunogenic cell death (ICD) HMGB1 RAGE 
This is a preview of subscription content, log in to check access.

References

  1. Ahmadzadehfar H, Biersack HJ, Ezziddin S. Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med. 2010;40(2):105–21.CrossRefPubMedGoogle Scholar
  2. Albrecht T. Liver diagnostics. Conservative alternatives to CT? Interview by Petra Eiden. MMW Fortschr Med. 1999;141(41):14.PubMedGoogle Scholar
  3. Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res. 2008;68:4026–30.CrossRefPubMedGoogle Scholar
  4. Beachy SH, Repasky EA. Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update. Cancer Immunol Immunother. 2008;57(6):759–75.CrossRefPubMedGoogle Scholar
  5. Bianchi ME. HMGB1 loves company. J Leukoc Biol. 2009;86:573–6.CrossRefPubMedGoogle Scholar
  6. Brown DB, Cook RD, Kerr JR, Gould JE, Pilgram TK, Darcy MD. Chemoembolization of hepatocellular carcinoma: patient status at presentation and outcome over 15 years at a single center. AJR Am J Roentgenol. 2008;190(3):608–15.CrossRefPubMedGoogle Scholar
  7. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol. 2001;35(3):421–30.CrossRefPubMedGoogle Scholar
  8. Bruix J, Sherman M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology. 2004;127:179–88.CrossRefGoogle Scholar
  9. Campana L, Bosurgi L, Rovere-Querini P. HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol. 2008;20:518–23.CrossRefPubMedGoogle Scholar
  10. Cheng BQ, Jia CQ, Liu CT, Lu XF, Zhong N, Zhang ZL, Fan W, Li YQ. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis. 2008;40(6):446–52.CrossRefPubMedGoogle Scholar
  11. Chung HW, Lee SG, Kim H, Hong DJ, Chung JB, Stroncek D, Lim JB. Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med. 2009;7:38.PubMedCentralCrossRefPubMedGoogle Scholar
  12. Dancey JE, Shepherd FA, Paul K, Sniderman KW, Houle S, Gabrys J, Hendler AL, Goin JE. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med. 2000;41(10):1673–81.PubMedGoogle Scholar
  13. De Nardo GL, Kroger LA, Mirick GR, Lamborn KR, De Nardo SJ. Analysis of antiglobulin (HAMA) response in a group of patients with B-lymphocytic malignancies treated with 131I-Lym-1. Int J Biol Markers. 1995;10(2):67–74.PubMedGoogle Scholar
  14. Delaunoit T, Alberts SR, Sargent DJ, Green E, Goldberg RM, Krook J, Fuchs C, Ramanathan RK, Williamson SK, Morton RF, Findlay BP. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol. 2005;16:425–9.CrossRefPubMedGoogle Scholar
  15. Dierckx R, Maes A, Peeters M, Van de Wiele C. FDG PET for monitoring response to local and locoregional therapy in HCC and liver metastases. Q J Nucl Med Mol Imaging. 2009;53(3):336–42.PubMedGoogle Scholar
  16. Dong YD, Cui L, Peng CH, Cheng DF, Han BS, Huang F. Expression and clinical significance of HMGB1 in human liver cancer: knockdown inhibits tumor growth and metastasis in vitro and in vivo. Oncol Rep. 2013;29(1):87–94.PubMedGoogle Scholar
  17. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134(6):1752–63.CrossRefPubMedGoogle Scholar
  18. Fahmueller YN, Nagel D, Hoffmann RT, Tatsch K, Jakobs T, Stieber P, Holdenrieder S. Predictive and prognostic value of circulating nucleosomes and serum biomarkers in patients with metastasized colorectal cancer undergoing Selective Internal Radiation Therapy. BMC Cancer. 2012;12:5.PubMedCentralCrossRefPubMedGoogle Scholar
  19. Fahmueller YN, Nagel D, Hoffmann RT, Tatsch K, Jakobs T, Stieber P, Holdenrieder S. Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients. Int J Cancer. 2013;132(10):2349–58.CrossRefPubMedGoogle Scholar
  20. Fehr Y, Holdenrieder S, Hoffmann RT, et al. Circulating nucleosomes in cancer patients with liver metastases undergoing selective internal radiation therapy using Yttrium-90 labelled microspheres. In: Gahan P, editor. Circulating nucleic acids in plasma and serum. New York/Heidelberg: Springer; 2011. p. 91–5.Google Scholar
  21. Friesen C, Lubatschofski A, Kotzerke J, Buchmann I, Reske SN, Debatin KM. Beta-irradiation used for systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in leukaemia cells. Eur J Nucl Med Mol Imaging. 2003;30(9):1251–61.CrossRefPubMedGoogle Scholar
  22. Geiger S, Holdenrieder S, Stieber P, Hamann GF, Bruening R, Ma J, Nagel D, Seidel D. Nucleosomes in serum of patients with early cerebral stroke. Cerebrovasc Dis. 2006;21(1–2):32–7.CrossRefPubMedGoogle Scholar
  23. Georgiades CS, Liapi E, Frangakis C, Park JU, Kim HW, Hong K, Geschwind JF. Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization. J Vasc Interv Radiol. 2006;17(10):1619–24.CrossRefPubMedGoogle Scholar
  24. Gomaa AI, Khan SA, Leen ELS, Waked I, Taylor-Robinson SD. Diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2009;15(11):1301–14.PubMedCentralCrossRefPubMedGoogle Scholar
  25. Hamilton SR, Aaltonen L. World Health Organization classification of tumours: pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2000.Google Scholar
  26. Holdenrieder S, Stieber P. Clinical use of circulating nucleosomes. Crit Rev Clin Lab Sci. 2009;46(1):1–24.CrossRefPubMedGoogle Scholar
  27. Holdenrieder S, Stief J, Bergner A, Gamarra F, Mitlewski A, Nagel D, Huber RM, Stieber P. Nucleosomes indicate the in vitro radiosensitivity of irradiated bronchoepithelial and lung cancer cells. Tumor Biol. 2004;25(5–6):321–6.CrossRefGoogle Scholar
  28. Jakobs TF, Hoffmann RT, Poepperl G, Schmitz A, Lutz J, Koch W, Tatsch K, Lubiensky A, Reiser MF, Helmberger T. Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using (90)Yttrium resin-microspheres. Eur Radiol. 2007;17(5):1320–30.CrossRefPubMedGoogle Scholar
  29. Jakobs TF, Hoffmann RT, Tatsch K, Trumm C, Reiser MF. Therapy response of liver tumors after selective internal radiation therapy. Radiologe. 2008;48(9):839–49.CrossRefPubMedGoogle Scholar
  30. Jiang W, Wang Z, Li X, Fan X, Duan Y. High-mobility group box 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Pathol Oncol Res. 2012;18(2):293–8.CrossRefPubMedGoogle Scholar
  31. Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C. Pathologic response and microdosimetry of Y-90 microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004;60(5):1552–63.CrossRefPubMedGoogle Scholar
  32. Kepp O, Tesniere A, Schlemmer F, Michaud M, Senovilla L, Zitvogel L, Kroemer G. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis. 2009;14:364–75.CrossRefPubMedGoogle Scholar
  33. Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, Michaud M, Sukkurwala AQ, Menger L, Zitvogel L, Kroemer G. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev. 2011;30(1):61–9.CrossRefPubMedGoogle Scholar
  34. Kohles N, Nagel D, Jüngst D, Durner J, Stieber P, Holdenrieder S. Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients. BMC Cancer. 2011;11:202.PubMedCentralCrossRefPubMedGoogle Scholar
  35. Kohles N, Nagel D, Jüngst D, Durner J, Stieber P, Holdenrieder S. Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy. Tumour Biol. 2012a;33(1):33–40.CrossRefPubMedGoogle Scholar
  36. Kohles N, Nagel D, Jüngst D, Stieber P, Holdenrieder S. Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy. Tumour Biol. 2012b;33(6):2401–9.CrossRefPubMedGoogle Scholar
  37. Kohles N, Nagel D, Jüngst D, Stieber P, Holdenrieder S. DNase is a prognostic marker in liver cancer patients receiving transarterial chemoembolization therapy. Int J Clin Pharmacol Ther. 2013;51(1):80–3.CrossRefPubMedGoogle Scholar
  38. Kostova N, Zlateva S, Ugrinova I, Pasheva E. The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem. 2010;337(1–2):251–8.CrossRefPubMedGoogle Scholar
  39. Krysko O, Løve Aaes T, Bachert C, Vandenabeele P, Krysko DV. Many faces of DAMPs in cancer therapy. Cell Death Dis. 2013;4:e631.PubMedCentralCrossRefPubMedGoogle Scholar
  40. Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 1995;31(5):1237–48.CrossRefPubMedGoogle Scholar
  41. Lee TK, Lau TC, Ng IO. Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines. Cancer Chemother Pharmacol. 2002;49(1):78–86.CrossRefPubMedGoogle Scholar
  42. Liu F, Zhang Y, Peng Z, Gao H, Xu L, Chen M. High expression of high mobility group box 1 (hmgb1) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy. J Transl Med. 2012;10:135.PubMedCentralCrossRefPubMedGoogle Scholar
  43. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734–9.CrossRefPubMedGoogle Scholar
  44. Llovet JM, Bruix J, Barcelona-Clinic Liver Cancer Group. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37(2):429–42.CrossRefPubMedGoogle Scholar
  45. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5:331–42.CrossRefPubMedGoogle Scholar
  46. Luo Y, Chihara Y, Fujimoto K, Sasahira T, Kuwada M, Fujiwara R, Fujii K, Ohmori H, Kuniyasu H. High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy. Eur J Cancer. 2013;49(3):741–51.CrossRefPubMedGoogle Scholar
  47. MacSween RNM, Burt AD, Portmann B. Pathology of the liver. 5th ed. London/Edinburgh/New York: Churchill Livingstone; 2007.Google Scholar
  48. Malafosse R, Penna C, Cunha AS, Nordlinger B. Surgical management of hepatic metastases from colorectal malignancies. Ann Oncol. 2001;12(7):887–94.CrossRefPubMedGoogle Scholar
  49. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med. 1996 Mar 14;334(11):693–9.CrossRefPubMedGoogle Scholar
  50. Mentha G, Majno P, Terraz S, et al. Treatment strategies for the management of advanced colorectal liver metastases detected synchronously with the primary tumor. Eur J Surg Oncol. 2007;33:76–83.CrossRefGoogle Scholar
  51. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, Rello-Varona S, Tailler M, Menger L, Vacchelli E, Galluzzi L, Ghiringhelli F, di Virgilio F, Zitvogel L, Kroemer G. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science. 2011;334(6062):1573–7.CrossRefPubMedGoogle Scholar
  52. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer-treatment. Cancer. 1981;47(1):207–14.CrossRefPubMedGoogle Scholar
  53. Naumnik W, Nilklinska W, Ossolinska M, et al. Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy. Folia Histochem Cytobiol. 2009;47:703–9.CrossRefPubMedGoogle Scholar
  54. Nordlinger B, Van Cutsem E, Gruenberger T, European Colorectal Metastases Treatment Group, Sixth International Colorectal Liver Metastases Workshop. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol. 2009;20(6):985–92.CrossRefPubMedGoogle Scholar
  55. Ozkan A, Fişkin K. Epirubicin HCl toxicity in human liver-derived hepatoma G2 cells. Pol J Pharmacol. 2004;56(4):435–44.PubMedGoogle Scholar
  56. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, Sohn JW, Yamada S, Maruyama I, Banerjee A, et al. High mobility group box 1 protein interacts with multiple toll-like receptors. Am J Physiol Cell Physiol. 2006;290:917–24.CrossRefGoogle Scholar
  57. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. Cancer J Clin. 2005;55(2):74–108.CrossRefGoogle Scholar
  58. Plati J, Bucur O, Khosravi-Far R. Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb). 2011;3(4):279–96.CrossRefGoogle Scholar
  59. Pusterla T, Nèmeth J, Stein I, Wiechert L, Knigin D, Marhenke S, Longerich T, Kumar V, Arnold B, Vogel A, Bierhaus A, Pikarsky E, Hess J, Angel P. Receptor for advanced glycation endproducts (RAGE) is a key regulator of oval cell activation and inflammation-associated liver carcinogenesis in mice. Hepatology. 2013;58(1):363–73.CrossRefPubMedGoogle Scholar
  60. Sangro B, Bilbao JI, Boan J, Martinez-Cuesta A, Benito A, Rodriguez J, Panizo A, Gil B, Inarrairaegui M, Herrero I, et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2006;66(3):792–800.CrossRefPubMedGoogle Scholar
  61. Schlag PM, Benhidjeb T, Stroszczynski C. Resection and local therapy for liver metastases. Best Pract Res Clin Gastroenterol. 2002;16(2):299–317.CrossRefPubMedGoogle Scholar
  62. Seifert JK, Morris DL. Prognostic factors after cryotherapy for hepatic metastases from colorectal cancer. Ann Surg. 1998;228(2):201–8.PubMedCentralCrossRefPubMedGoogle Scholar
  63. Shang GH, Jia CQ, Tian H, et al. Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer. Respir Med. 2009;103:1949–53.CrossRefPubMedGoogle Scholar
  64. Sheng X, Du X, Zhang X, et al. Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CAFRA 21–1, and CEA levels. Croat Med J. 2009;50:455–64.PubMedCentralCrossRefPubMedGoogle Scholar
  65. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol. 2010;28:367–88.CrossRefPubMedGoogle Scholar
  66. Stoetzer OJ, Fersching DM, Salat C, Steinkohl O, Gabka CJ, Hamann U, Braun M, Feller AM, Heinemann V, Siegele B, Nagel D, Holdenrieder S. Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy. Tumour Biol. 2013;34(1):81–90.CrossRefPubMedGoogle Scholar
  67. Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 2008;15:3–12.CrossRefPubMedGoogle Scholar
  68. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al. New guidelines to evaluate the response to treatment in solid Tumors. J Natl Cancer Inst. 2000;92(3):205–16.CrossRefPubMedGoogle Scholar
  69. Vilana R, Bruix J, Bru C, Ayuso C, Solé M, Rodés J. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology. 1992;16(2):353–7.CrossRefPubMedGoogle Scholar
  70. Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med. 2010;61:317–28.PubMedCentralCrossRefPubMedGoogle Scholar
  71. Vogl TJ, Zangos S, Eichler K, Yakoub D, Nabil M. Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update. Eur Radiol. 2007;17(4):1025–34.CrossRefPubMedGoogle Scholar
  72. Vogl TJ, Naguib NN, Nour-Eldin NE, Rao P, Emami AH, Zangos S, Nabil M, Abdelkader A. Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J Radiol. 2009;72(3):505–16.CrossRefPubMedGoogle Scholar
  73. Weiner LM, Lotze MT. Tumor-cell death, autophagy, and immunity. N Engl J Med. 2012;366(12):1156–8.PubMedCentralCrossRefPubMedGoogle Scholar
  74. Weiss L, Grundmann E, Torhorst J, Hartveit F, Moberg I, Eder M, Fenogliopreiser CM, Napier J, Horne CHW, Lopez MJ, et al. Hematogenous metastatic patterns in colonic-carcinoma – an analysis of 1541 necropsies. J Pathol. 1986;150(3):195–203.CrossRefPubMedGoogle Scholar
  75. Winterer JT, Kotter E, Ghanem N, Langer M. Detection and characterization of benign focal liver lesions with multislice CT. Eur Radiol. 2006;16(11):2427–43.CrossRefPubMedGoogle Scholar
  76. Wittwer C, Boeck S, Heinemann V, Haas M, Stieber P, Nagel D, Holdenrieder S. Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy. Int J Cancer. 2013a;133(11):2619–30.PubMedGoogle Scholar
  77. Wittwer C, Boeck S, Heinemann V, Haas M, Stieber P, Nagel D, Holdenrieder S. Soluble receptor of advanced glycation end products (sRAGE) indicates response to chemotherapy in pancreatic cancer patients. Int J Clin Pharmacol Ther. 2013b;51(1):67–9.CrossRefPubMedGoogle Scholar
  78. Yan W, Chang Y, Liang X, Cardinal JS, Huang H, Thorne SH, Monga SP, Geller DA, Lotze MT, Tsung A. High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology. 2012;55(6):1863–75.CrossRefPubMedGoogle Scholar
  79. Yang H, Lundbäck P, Ottosson L, Erlandsson-Harris H, Venereau E, Bianchi ME, Al-Abed Y, Andersson U, Tracey KJ, Antoine DJ. Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med. 2012;18:250–9.PubMedCentralCrossRefPubMedGoogle Scholar
  80. Zhang JH, Xu M. Apoptotic DNA fragmentation and tissue homeostasis. Trends Cell Biol. 2002;12:84–9.CrossRefPubMedGoogle Scholar
  81. Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res. 2010;16(12):3100–4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  1. 1.Department of OtorhinolaryngologyHelios-Klinikum ErfurtErfurtGermany
  2. 2.Institute of Clinical Chemistry and Clinical PharmacologyUniversity Hospital BonnBonnGermany

Personalised recommendations